Miguel Angel
Canales Albendea
Consultor Médico
Publicacions (113) Publicacions de Miguel Angel Canales Albendea
2024
-
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Blood cancer discovery, Vol. 5, Núm. 1, pp. 21-33
2023
-
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Cancers, Vol. 15, Núm. 5
-
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
Frontiers in Medicine, Vol. 10
-
Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation
Disease Markers, Vol. 2023
-
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients with Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis
HemaSphere
-
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
eClinicalMedicine, Vol. 63
2022
-
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100
-
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33
-
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494
-
IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065
-
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Cancers, Vol. 14, Núm. 3
2021
-
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
Investigational New Drugs, Vol. 39, Núm. 4, pp. 1028-1035
-
COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors
Cancer
-
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310
-
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid
Expert Review of Hematology
-
Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak
Leukemia and Lymphoma
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology and Oncology
2020
-
Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document
Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 811-817
-
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
European heart journal, Vol. 41, Núm. 18, pp. 1720-1729